Compare Freshworks Inc (FRSH) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Nuwellis Inc — how do they compare? Freshworks Inc trades at $13.75 (market cap $3.56B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Freshworks Inc is far larger — about 1618.2× Nuwellis Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Nuwellis Inc for 26 Days on average.
| FRSH | NUWE | |
|---|---|---|
Market Cap | $3.56B | $2.20M |
Volume | 9,066,454 | 121,544 |
Sector | Technology | Health |
52-Week High | $13.92 | $146.65 |
52-Week Low | $6.88 | $0.68 |
Typical Hold Time | 39 Days | 26 Days |
Enterprise Value | $2.93B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.60, down 1.16% today, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company achieved its first GAAP profitability in Q2 2026 with revenue growth of 16% year-over-year, while maintaining impressive gross margins of 84.96%. Recent developments include FedRAMP certification progress and leadership in Gartner's ITSM Magic Quadrant.
The outlook remains positive with analyst consensus at $14.60 target (7.4% upside) and balanced buy/hold ratings. Key opportunities include AI monetization and enterprise expansion, while risks involve competitive SaaS pressures and execution on growth targets. The stock presents a compelling value proposition with improving profitability metrics.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
